血红蛋白-血小板指数作为非特指型弥漫性大B细胞淋巴瘤的新型预后预测指标:贫血和血小板减少与淋巴瘤细胞产生IL-6相关
本研究在94例非特指型弥漫性大B细胞淋巴瘤(DLBCL NOS)验证队列中证实血红蛋白-血小板指数(HPI)可区分无进展生存期(PFS)和总生存期,并在160例患者中比较HPI与NCCN-IPI、GPS和PA评分,发现高HPI患者结局显著更差,HPI可独立于NCCN-IPI预测预后,且HPI预测PFS的敏感性高于GPS、与PA评分几乎相同;淋巴瘤细胞IL-6阳性(75/111例)患者血红蛋白水平和血小板计数显著低于IL-6阴性(36/111例)患者,提示淋巴瘤细胞产生的IL-6参与DLBCL NOS患者的贫血和血小板减少。
要点
- 在94例验证队列中,HPI可区分DLBCL NOS患者的PFS和总生存期。
- 在160例患者中,高HPI评分患者结局显著更差,HPI可独立于NCCN-IPI预测预后。
- HPI预测PFS的敏感性高于GPS,与PA评分几乎相同。
核心结论
- HPI在验证队列中可有效区分DLBCL NOS患者的PFS和总生存期,高HPI评分患者结局显著更差,HPI可独立于NCCN-IPI预测预后。
- HPI预测PFS的敏感性高于GPS,与PA评分几乎相同。
- 淋巴瘤细胞IL-6阳性患者血红蛋白水平和血小板计数显著低于IL-6阴性患者,提示淋巴瘤细胞产生的IL-6参与DLBCL NOS患者的贫血和血小板减少。
研究设计与样本
- 研究纳入新验证队列94例DLBCL NOS患者,并进一步使用包含衍生队列66例和验证队列94例共160例患者进行比较分析。
- 通过免疫组织化学染色判断淋巴瘤细胞IL-6表达,比较IL-6阳性(75/111例)与IL-6阴性(36/111例)患者的血红蛋白水平和血小板计数。
主要发现
- 在94例验证队列中,HPI可有效区分PFS和总生存期。
- 在160例患者中,高HPI评分患者结局显著更差,HPI可独立于NCCN-IPI预测DLBCL NOS预后。
- HPI预测PFS的敏感性高于GPS,与PA评分几乎相同。
- 淋巴瘤细胞IL-6阳性(75/111例)患者血红蛋白水平和血小板计数显著低于IL-6阴性(36/111例)患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously reported that a novel haemoglobin-platelet index (HPI) based on anaemia and thrombocytopenia was useful to predict the prognosis of patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS). Here, we analyse the utility of HPI in a new validation cohort with DLBCL NOS (n = 94). As a result, we confirm that HPI was effective for differentiating progression-free survival (PFS) and overall survival in this validation cohort. So, we further compare the utility of HPI with previously reported prognostic markers such as the National Comprehensive Center Network-International Prognostic Index (NCCN-IPI), Glasgow prognostic score (GPS), and platelet-albumin (PA) score, using a larger number of 160 patients consisting of the derivation cohort (n = 66) and a validation cohort (n = 94). As a result, the patients with a higher HPI score had significantly worse outcomes, and HPI predicted the prognosis of DLBCL NOS independently of NCCN-IPI. HPI was more sensitive than GPS and almost the same as PA score in predicting PFS. Moreover, the patients whose lymphoma cells were positive for interleukin-6 (IL-6) (75/111 cases) judged by immunohistochemical staining had significantly lower haemoglobin levels and platelet counts than IL-6-negative cases (36/111 cases), suggesting the involvement of IL-6 produced by lymphoma cells in anaemia and thrombocytopenia in DLBCL NOS patients.
引用
- Taniguchi T, Nakayama S, Tanaka H, et al. Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells. Br J Haematol. 2022. PMID: 35451502. doi:10.1111/bjh.18208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。